FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2514934032> ?p ?o ?g. }

• W2514934032 endingPage "4806" @default.
• W2514934032 startingPage "4799" @default.
• W2514934032 abstract "To evaluate the immunogenicity and safety of the quadrivalent HPV (qHPV) vaccine in HIV-positive women over 24 months. Between November 2008 and December 2012, 372 women aged 15 and older were enrolled from 14 Canadian HIV outpatient clinics in an open label cohort study. The qHPV vaccine (0.5 mL) was administered intramuscularly at months 0, 2 and 6. The primary study endpoint was seroconversion to any of the HPV types targeted by the qHPV vaccine. Antibody levels were measured at 0, 2, 7, 12, 18, and 24 months. Adverse events were recorded throughout. Of 372 participants enrolled, 310 (83%) received at least one dose of the qHPV vaccine and 277 (74%) received all three doses. Ninety-five percent (293/308) were seronegative for at least one vaccine type at baseline. The median age was 38 years (IQR 32–45, range 15–66), 36% were white, 44% black and 13% were of Indigenous origin. Seventy-two percent of participants had a suppressed HIV viral load (VL < 40 c/ml) at baseline, with a median CD4 count of 510 cells/mm3 (376–695). Month 7 HPV type-specific seroconversion rates were 99.0%, 98.7%, 98.1% and 93.6% for HPV types 6, 11, 16 and 18 respectively in the per-protocol population. Participants with suppressed HIV VL at first vaccine had a 1.74–3.05 fold higher peak antibody response compared to those without (p from 0.006 to <0.0001). This study is the first to examine the qHPV vaccine in HIV-positive women out to 24 months and the first to include HIV-positive women through to age 66. The qHPV vaccine was well tolerated, and highly immunogenic. As women with suppressed viral load had higher antibody responses, planning HPV vaccination to occur when persons are virologically suppressed would be optimal for maximizing immune response. Findings provide strong evidence that older HIV-positive women can still benefit from HPV vaccination. Clinical trial registration: http://www.isrctn.com/ISRCTN33674451" @default.
• W2514934032 created "2016-09-16" @default.
• W2514934032 creator A5001045724 @default.
• W2514934032 creator A5007414173 @default.
• W2514934032 creator A5010323243 @default.
• W2514934032 creator A5010815891 @default.
• W2514934032 creator A5013999934 @default.
• W2514934032 creator A5019449352 @default.
• W2514934032 creator A5026415367 @default.
• W2514934032 creator A5027614467 @default.
• W2514934032 creator A5045151498 @default.
• W2514934032 creator A5049189066 @default.
• W2514934032 creator A5053245473 @default.
• W2514934032 creator A5053655124 @default.
• W2514934032 creator A5055759059 @default.
• W2514934032 creator A5061614395 @default.
• W2514934032 creator A5068163031 @default.
• W2514934032 creator A5070026019 @default.
• W2514934032 creator A5076991437 @default.
• W2514934032 creator A5079746460 @default.
• W2514934032 creator A5080324507 @default.
• W2514934032 creator A5080613190 @default.
• W2514934032 creator A5082552150 @default.
• W2514934032 creator A5085361999 @default.
• W2514934032 date "2016-09-01" @default.
• W2514934032 modified "2023-10-11" @default.
• W2514934032 title "HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine" @default.
• W2514934032 cites W1967598361 @default.
• W2514934032 cites W1975989709 @default.
• W2514934032 cites W1977087963 @default.
• W2514934032 cites W2039187099 @default.
• W2514934032 cites W2073773795 @default.
• W2514934032 cites W2081047239 @default.
• W2514934032 cites W2081765996 @default.
• W2514934032 cites W2089348790 @default.
• W2514934032 cites W2108018524 @default.
• W2514934032 cites W2109263605 @default.
• W2514934032 cites W2125726664 @default.
• W2514934032 cites W2139808322 @default.
• W2514934032 cites W2145518288 @default.
• W2514934032 cites W2155314494 @default.
• W2514934032 cites W2318581442 @default.
• W2514934032 doi "https://doi.org/10.1016/j.vaccine.2016.08.016" @default.
• W2514934032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27544584" @default.
• W2514934032 hasPublicationYear "2016" @default.
• W2514934032 type Work @default.
• W2514934032 sameAs 2514934032 @default.
• W2514934032 citedByCount "35" @default.
• W2514934032 countsByYear W25149340322017 @default.
• W2514934032 countsByYear W25149340322018 @default.
• W2514934032 countsByYear W25149340322019 @default.
• W2514934032 countsByYear W25149340322020 @default.
• W2514934032 countsByYear W25149340322021 @default.
• W2514934032 countsByYear W25149340322022 @default.
• W2514934032 countsByYear W25149340322023 @default.
• W2514934032 crossrefType "journal-article" @default.
• W2514934032 hasAuthorship W2514934032A5001045724 @default.
• W2514934032 hasAuthorship W2514934032A5007414173 @default.
• W2514934032 hasAuthorship W2514934032A5010323243 @default.
• W2514934032 hasAuthorship W2514934032A5010815891 @default.
• W2514934032 hasAuthorship W2514934032A5013999934 @default.
• W2514934032 hasAuthorship W2514934032A5019449352 @default.
• W2514934032 hasAuthorship W2514934032A5026415367 @default.
• W2514934032 hasAuthorship W2514934032A5027614467 @default.
• W2514934032 hasAuthorship W2514934032A5045151498 @default.
• W2514934032 hasAuthorship W2514934032A5049189066 @default.
• W2514934032 hasAuthorship W2514934032A5053245473 @default.
• W2514934032 hasAuthorship W2514934032A5053655124 @default.
• W2514934032 hasAuthorship W2514934032A5055759059 @default.
• W2514934032 hasAuthorship W2514934032A5061614395 @default.
• W2514934032 hasAuthorship W2514934032A5068163031 @default.
• W2514934032 hasAuthorship W2514934032A5070026019 @default.
• W2514934032 hasAuthorship W2514934032A5076991437 @default.
• W2514934032 hasAuthorship W2514934032A5079746460 @default.
• W2514934032 hasAuthorship W2514934032A5080324507 @default.
• W2514934032 hasAuthorship W2514934032A5080613190 @default.
• W2514934032 hasAuthorship W2514934032A5082552150 @default.
• W2514934032 hasAuthorship W2514934032A5085361999 @default.
• W2514934032 hasBestOaLocation W25149340322 @default.
• W2514934032 hasConcept C126322002 @default.
• W2514934032 hasConcept C142462285 @default.
• W2514934032 hasConcept C159654299 @default.
• W2514934032 hasConcept C197934379 @default.
• W2514934032 hasConcept C203014093 @default.
• W2514934032 hasConcept C22070199 @default.
• W2514934032 hasConcept C2777451964 @default.
• W2514934032 hasConcept C2780868878 @default.
• W2514934032 hasConcept C2908647359 @default.
• W2514934032 hasConcept C3013748606 @default.
• W2514934032 hasConcept C71924100 @default.
• W2514934032 hasConcept C72563966 @default.
• W2514934032 hasConcept C99454951 @default.
• W2514934032 hasConceptScore W2514934032C126322002 @default.
• W2514934032 hasConceptScore W2514934032C142462285 @default.
• W2514934032 hasConceptScore W2514934032C159654299 @default.
• W2514934032 hasConceptScore W2514934032C197934379 @default.
• W2514934032 hasConceptScore W2514934032C203014093 @default.
• W2514934032 hasConceptScore W2514934032C22070199 @default.

• next